Study #2016-0889
An Open-label, Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Combination with Venetoclax in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia, High-Risk Myelodysplastic Syndrome or T Acute Lymphoblastic Leukemia/Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Daratumumab
Description
This phase II trial studies how well daratumumab works in treating patients with acute myeloid leukemia that has come back or does not respond to treatment or high-risk myelodysplastic syndrome. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Information and next steps
Disease:
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Study phase:
II
Physician name:
Gautam Borthakur
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.